Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
65.14
+1.02 (1.59%)
May 11, 2026, 10:31 AM EDT - Market open
Halozyme Therapeutics Employees
Halozyme Therapeutics had 423 employees as of December 31, 2025. The number of employees increased by 73 or 20.86% compared to the previous year.
Employees
423
Change (1Y)
73
Growth (1Y)
20.86%
Revenue / Employee
$3,301,681
Profits / Employee
$749,147
Market Cap
7.72B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 423 | 73 | 20.86% |
| Dec 31, 2024 | 350 | -23 | -6.17% |
| Dec 31, 2023 | 373 | -20 | -5.09% |
| Dec 31, 2022 | 393 | 248 | 171.03% |
| Dec 31, 2021 | 145 | 9 | 6.62% |
| Dec 31, 2020 | 136 | 4 | 3.03% |
| Dec 31, 2019 | 132 | -149 | -53.02% |
| Dec 31, 2018 | 281 | 26 | 10.20% |
| Dec 31, 2017 | 255 | -4 | -1.54% |
| Dec 31, 2016 | 259 | 43 | 19.91% |
| Dec 31, 2015 | 216 | 63 | 41.18% |
| Dec 31, 2014 | 153 | -17 | -10.00% |
| Dec 31, 2013 | 170 | 18 | 11.84% |
| Dec 31, 2012 | 152 | 17 | 12.59% |
| Dec 31, 2011 | 135 | 33 | 32.35% |
| Dec 31, 2010 | 102 | -38 | -27.14% |
| Dec 31, 2009 | 140 | 10 | 7.69% |
| Dec 31, 2008 | 130 | 38 | 41.30% |
| Dec 31, 2007 | 92 | 52 | 130.00% |
| Dec 31, 2006 | 40 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| ImmunityBio | 691 |
| Vaxcyte | 507 |
| Rhythm Pharmaceuticals | 414 |
| Mirum Pharmaceuticals | 372 |
| Krystal Biotech | 295 |
| Kymera Therapeutics | 253 |
| Nuvalent | 228 |
HALO News
- 3 days ago - Halozyme announces global collaboration and license agreement with GSK - TheFly
- 4 days ago - Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets - PRNewsWire
- 4 days ago - Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis - TheFly
- 5 days ago - Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology - PRNewsWire
- 5 days ago - Halozyme Therapeutics Transcript: AGM 2026 - Transcripts
- 10 days ago - Halozyme to Report First Quarter 2026 Financial and Operating Results - PRNewsWire
- 10 days ago - Halozyme names Darren Snellgrove as CFO - TheFly
- 11 days ago - Halozyme Appoints Darren Snellgrove as Chief Financial Officer - PRNewsWire